Biora Therapeutics, Inc.
General ticker "BIOR" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.3M (TTM average)
Biora Therapeutics, Inc. does not follow the US Stock Market performance with the rate: -2.4%.
Estimated limits based on current volatility of 0.0%: low 0.22$, high 0.22$
Factors to consider:
- Total employees count: 54 as of 2022
- Top business risk factors: Operational and conduct risks, Pandemic risks, Capital raising, Supply chain disruptions, Litigation risks
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [3.88$, 19.73$]
- 2024-12-30 to 2025-12-30 estimated range: [1.41$, 8.06$]
Financial Metrics affecting the BIOR estimates:
- Negative: with PPE of -0.3 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -240.74 <= 0.33
- Negative: negative Industry operating cash flow (median)
- Negative: negative Net income
- Negative: Shareholder equity ratio, % of -324.91 <= 18.93
- Negative: Interest expense per share per price, % of 48.72 > 3.41
- Negative: negative Industry operating income (median)
Short-term BIOR quotes
Long-term BIOR plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $1.25MM | $0.30MM | $0.00MM |
| Operating Expenses | $119.08MM | $62.09MM | $67.15MM |
| Operating Income | $-117.84MM | $-61.78MM | $-67.14MM |
| Non-Operating Income | $-60.80MM | $12.53MM | $-57.28MM |
| Interest Expense | $12.64MM | $10.99MM | $9.81MM |
| R&D Expense | $45.78MM | $24.05MM | $29.84MM |
| Income(Loss) | $-178.64MM | $-49.25MM | $-124.42MM |
| Taxes | $-0.12MM | $-0.42MM | $-0.09MM |
| Other Income(Loss) | $-68.89MM | $10.67MM | $0.00MM |
| Profit(Loss)* | $-178.52MM | $-48.83MM | $-124.11MM |
| Stockholders Equity | $-84.98MM | $-102.29MM | $-101.42MM |
| Inventory | $2.15MM | $0.00MM | $0.00MM |
| Assets | $108.84MM | $53.52MM | $31.21MM |
| Operating Cash Flow | $-167.49MM | $-64.42MM | $-48.50MM |
| Capital expenditure | $0.85MM | $0.79MM | $0.10MM |
| Investing Cash Flow | $-1.24MM | $-0.79MM | $2.44MM |
| Financing Cash Flow | $165.05MM | $7.30MM | $30.78MM |
| Earnings Per Share** | $-46.42 | $-6.40 | $-78.69 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.